Abstract
RNA interference (RNAi) provides a powerful method for gene silencing in eukaryotic cells, including proliferating mammalian cells. Here, we determined whether RNAi could be utilized to inhibit the expression of proteases implicated in the extracellular matrix degradation, which is characteristic of tumor progression. We have previously shown that antisense stable clones of uPAR and cathepsin B were less invasive and did not form tumors when injected intracranially ex vivo. Since antisense-mediated gene silencing does not completely inhibit the translation of target mRNA and high molar concentrations of antisense molecules are required to achieve gene silencing, we used the RNAi approach to silence uPAR and cathepsin B in this study. We found that the expression of double-stranded RNA leads to the efficient and specific inhibition of endogenous uPAR and cathepsin B protein expression in glioma cell lines as determined by Western blotting. We also found the RNAi of uPAR and cathepsin B reduces glioma cell invasion and angiogenesis in in vitro and in vivo models. Intratumoral injections of plasmid vectors expressing hpRNA for uPAR and cathepsin B resulted in the regression of pre-established intracranial tumors. Further, RNAi for uPAR and cathepsin B inhibited cell proliferation and reduced the levels of pERK and pFAK compared to controls. Taken together, our findings indicate for the first time that RNAi operates in human glioma cells with potential application for cancer gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- RNAi:
-
RNA interference
- uPA:
-
urokinase-type plasminogen activator
- uPAR:
-
uPA receptor
- CMV:
-
cytomegalovirus
- SV40:
-
simian virus type 40
- PCR:
-
polymerase chain reaction
- PBS:
-
phosphate-buffered saline
- FITC:
-
fluoresceine-5-isothiocyanate
- DiI:
-
1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanineperchlorate
- DiO:
-
3,3'-dioctadecyloxacarbocyanine perchlorate
- GFP:
-
green fluorescent protein
- ECM:
-
extracellular matrix
References
Aguirre Ghiso JA . (2002). Oncogene, 21, 2513–2524.
Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K and Ossowski L . (2001). Mol. Biol. Cell, 12, 863–879.
Alonso DF, Tejera AM, Farias EF, Bal de Kier JE and Gomez DE . (1998). Anticancer Res., 18, 4499–4504.
Andreasen PA, Kjoller L, Christensen L and Duffy MJ . (1997). Int. J. Cancer, 72, 1–22.
Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A and Malvy C . (2002). Biochem. Biophys. Res. Commun., 296, 1000–1004.
Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF and Lah TT . (2003). Biol. Chem., 384, 447–455.
Coulibaly S, Schwihla H, Abrahamson M, Albini A, Cerni C, Clark JL, Ng KM, Katunuma N, Schlappack O, Glossl J and Mach L . (1999). Int. J. Cancer, 83, 526–531.
Creemers LB, Hoeben KA, Jansen DC, Buttle DJ, Beertsen W and Everts V . (1998). Matrix Biol., 16, 575–584.
Evans DM, Sloan-Stakleff K, Arvan M and Guyton DP . (1998). Clin. Exp. Metast., 16, 353–357.
Gladson CL, Pijuan-Thompson V, Olman MA, Gillespie GY and Yacoub IZ . (1995). Am. J. Pathol., 146, 1150–1160.
Go Y, Chintala SK, Mohanam S, Gokaslan Z, Venkaiah B, Bjerkvig R, Oka K, Nicolson GL, Sawaya R and Rao JS . (1997). Clin. Exp. Metast., 15, 440–446.
Guicciardi ME, Miyoshi H, Bronk SF and Gores GJ . (2001). Am. J. Pathol., 159, 2045–2054.
Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP and Rabbani SA . (2000). FASEB J., 14, 1400–1410.
Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA and Castellino FJ . (2000). Cancer Res., 60, 5839–5847.
Hazen LG, Bleeker FE, Lauritzen B, Bahns S, Song J, Jonker A, Van Driel BE, Lyon H, Hansen U, Kohler A and Van Noorden CJ . (2000). J. Histochem. Cytochem., 48, 1421–1430.
Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V and Brunner N . (1996). Clin. Exp. Metast., 14, 297–307.
Jiang Y, Goldberg ID and Shi YE . (2002). Oncogene, 21, 2245–2252.
Jo M, Thomas KS, O'Donnell DM and Gonias SL . (2003). J. Biol. Chem., 278, 1642–1646.
Keppler D, Sameni M, Moin K, Mikkelsen T, Diglio CA and Sloane BF . (1996). Biochem. Cell. Biol., 74, 799–810.
Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR and Folkman J . (2001). Cancer Res., 61, 7669–7674.
Kjoller L . (2002). Biol. Chem., 383, 5–19.
Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H and Terao T . (1993). Jpn. J. Cancer Res., 84, 633–640.
Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Gunzler WA, Janicke F and Graeff H . (1991). J. Biol. Chem., 266, 5147–5152.
Konduri SD, Yanamandra N, Siddique K, Joseph A, Dinh DH, Olivero WC, Gujrati M, Kouraklis G, Swaroop A, Kyritsis AP and Rao JS . (2002). Oncogene, 21, 8705–8712.
Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brunner N . (2000). Clin. Cancer Res., 6, 505–511.
Kostoulas G, Lang A, Nagase H and Baici A . (1999). FEBS Lett., 455, 286–290.
Krueger S, Haeckel C, Buehling F and Roessner A . (1999). Cancer Res., 59, 6010–6014.
Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K and Jain RK . (1992). Cancer Res., 52, 6553–6560.
Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M and Yeh P . (1998). Gene Therapy, 5, 1105–1113.
Lochter A, Galosy S, Muschler J, Freedman N, Werb Z and Bissell MJ . (1997). J. Cell. Biol., 139, 1861–1872.
McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ and Kay MA . (2002). Nature, 418, 38–39.
McGuire PG, Jones TR, Talarico N, Warren E and Das A . (2003). Invest. Ophthalmol. Vis. Sci., 44, 2736–2742.
Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF and Rosenblum ML . (1995). J. Neurosurg., 83, 285–290.
Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA and Rosenberg S . (1996). Cancer Res., 56, 2428–2433.
Mohanam S, Chandrasekar N, Yanamandra N, Khawar S, Mirza F, Dinh DH, Olivero WC and Rao JS . (2002). Oncogene, 21, 7824–7830.
Mohan PM, Chintala SK, Mohanam S, Gladson CL, Kim ES, Gokaslan ZL, Lakka SS, Roth JA, Fang B, Sawaya R, Kyritsis AP and Rao JS . (1999). Cancer Res., 59, 3369–3373.
Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R and Rao JS . (1997). Oncogene, 14, 1351–1359.
Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D and Rao JS . (1993). Cancer Res., 53, 4143–4147.
Murphy G, Atkinson S, Ward R, Gavrilovic J and Reynolds JJ . (1992). Ann. NY Acad. Sci., 667, 1–12.
Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F and Comoglio PM . (1995). J. Biol. Chem., 270, 603–611.
Nguyen DH, Hussaini IM and Gonias SL . (1998). J. Biol. Chem., 273, 8502–8507.
Planus E, Barlovatz-Meimon G, Rogers RA, Bonavaud S, Ingber DE and Wang N . (1997). J. Cell. Sci., 110, 1091–1098.
Redwood SM, Liu BC, Weiss RE, Hodge DE and Droller MJ . (1992). Cancer, 69, 1212–1219.
Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G and Sloane BF . (1994). Cancer Res., 54, 6027–6031.
Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H and Schmitt M . (1998). Int. J. Oncol., 13, 893–906.
Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, Kruger A and Magdolen V . (2002). FEBS Lett., 528, 212–216.
Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L and Graeff H . (1992). Biol. Chem. Hoppe Seyler, 373, 611–622.
Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M and Sloane BF . (1995). Prostate, 26, 171–178.
Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL and Rao JS . (1995). Clin. Exp. Metast., 13, 49–56.
Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P and Lieberman J . (2003). Nat. Med., 9, 347–351.
Strojnik T, Kos J, Zidanik B, Golouh R and Lah T . (1999). Clin. Cancer Res., 5, 559–567.
Szpaderska AM and Frankfater A . (2001). Cancer Res., 61, 3493–3500.
Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A and Hall WA . (2002). J. Natl. Cancer Inst., 94, 597–606.
Wilda M, Fuchs U, Wossmann W and Borkhardt A . (2002). Oncogene, 21, 5716–5724.
Xia H, Mao Q, Paulson HL and Davidson BL . (2002). Nat. Biotechnol., 20, 1006–1010.
Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicolson GL and Rao JS . (1994). Cancer Res., 54, 5016–5020.
Zamore PD . (2001). Nat. Struct. Biol., 8, 746–750.
Acknowledgements
We would like to thank Noorjehan Ali for technical assistance, Tina Wilson for preparing the manuscript and Sushma Jasti and Diana Meister for manuscript review. Supported by National Cancer Institute Grants CA 85216, CA 75557 and CA 92393 (to JSR).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gondi, C., Lakka, S., Dinh, D. et al. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23, 8486–8496 (2004). https://doi.org/10.1038/sj.onc.1207879
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207879
Keywords
This article is cited by
-
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
Journal of Translational Medicine (2022)
-
uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions
Bone Research (2020)
-
Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor
BMC Cancer (2014)
-
Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells
Oncogene (2014)
-
Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression
Oncogene (2014)